Related Experiment Video
Updated: Mar 3, 2026

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.4K
GLP-1 Demand Shock: Work Reallocation, Productivity Decline, and Training Implications Across General and Bariatric
Ramsey Michael Dallal1, Aditya Das1, Edmund A Pribitkin2
1Department of Surgery, Jefferson Health, Philadelphia, PA; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Annals of Surgery
|March 2, 2026
Summary
No abstract available in PubMed .
Related Concept Videos
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326

